

Jason Valent

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/289711/publications.pdf>

Version: 2024-02-01

33
papers

499
citations

949033

11
h-index

799663

21
g-index

33
all docs

33
docs citations

33
times ranked

879
citing authors

#	ARTICLE	IF	CITATIONS
1	Supra-normal left ventricular ejection fraction in cardiac amyloidosis. <i>Clinical Research in Cardiology</i> , 2023, 112, 441-443.	1.5	2
2	Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia). <i>Advances in Hematology</i> , 2022, 2022, 1-9.	0.6	6
3	DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Seminars in Hematology</i> , 2021, 58, 45-55.	1.8	8
4	Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. <i>British Journal of Haematology</i> , 2021, 193, 1213-1219.	1.2	25
5	Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy. <i>Blood Cancer Journal</i> , 2021, 11, 121.	2.8	6
6	Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 91, 102595.	0.6	2
7	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 10.	2.8	53
8	Treatment of relapsed multiple myeloma: Evidence-based recommendations. <i>Blood Reviews</i> , 2020, 39, 100616.	2.8	43
9	Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. <i>British Journal of Haematology</i> , 2020, 189, 1136-1140.	1.2	25
10	Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2020, 38, 353-362.	0.8	14
11	Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis. <i>Blood</i> , 2020, 136, 21-21.	0.6	9
12	Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. <i>Blood</i> , 2020, 136, 48-50.	0.6	11
13	A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase. <i>Blood</i> , 2020, 136, 32-33.	0.6	0
14	Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score. <i>Blood</i> , 2020, 136, 29-30.	0.6	2
15	Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144). <i>Blood</i> , 2020, 136, 26-27.	0.6	7
16	Outcomes in AL Amyloidosis: A Single Institution Experience. <i>Blood</i> , 2020, 136, 32-32.	0.6	0
17	Daratumumab proves safe and highly effective in AL amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 342-344.	1.2	46
18	Palliative Care in Patients With Multiple Myeloma. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 1113-1118.	0.6	6

#	ARTICLE	IF	CITATIONS
19	Progression with clinical features is associated with worse subsequent survival in multiple myeloma. American Journal of Hematology, 2019, 94, 439-445.	2.0	12
20	Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 397-405.	0.2	13
21	Monoclonal gammopathy of undetermined significance: A primary care guide. Cleveland Clinic Journal of Medicine, 2019, 86, 39-46.	0.6	8
22	Progress in diagnosing and managing cardiac amyloidosis. Cleveland Clinic Journal of Medicine, 2019, 86, 29-37.	0.6	2
23	Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 197-202.	1.4	51
24	Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma. Blood, 2018, 132, 1899-1899.	0.6	3
25	Diagnostic challenges in POEMS syndrome presenting with polyneuropathy: A case series. Journal of the Neurological Sciences, 2017, 378, 170-174.	0.3	7
26	Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PLoS ONE, 2017, 12, e0172996.	1.1	20
27	Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes. Blood and Lymphatic Cancer: Targets and Therapy, 2016, 6, 21.	1.2	2
28	Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure. Journal of the American College of Cardiology, 2016, 67, 2941-2948.	1.2	84
29	Once Weekly Subcutaneous Bortezomib, Cyclophosphamide, and Dexamethasone As Induction Therapy for All AL Amyloidosis. Blood, 2016, 128, 5813-5813.	0.6	2
30	Response-Adapted Therapy for Newly Diagnosed Myeloma. Blood, 2016, 128, 3606-3606.	0.6	0
31	A 70-Year-Old Man With Large Cervical and Mediastinal Lymphadenopathies. Chest, 2015, 148, e8-e13.	0.4	4
32	Emerging Advances in the Management of Cardiac Amyloidosis. Current Cardiology Reports, 2015, 17, 100.	1.3	19
33	Solitary extramedullary plasmacytoma of the penis. Urology Annals, 2014, 6, 242.	0.3	7